TRVI Trevi Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1563880 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY-8.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-24.7%
ROA-23.8%
ROIC (approx.)-27.2%
Asset turnover—
Leverage & solvency
Liabilities / assets2.6%
Debt / equity0.00x
Current ratio38.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $19.06M | $15.15M | $9.94M | $6.19M | $10.09M | $9.39M | $7.81M | $9.33M |
| SG&A expense | $5.42M | $5.36M | $4.97M | $4.03M | $3.83M | $4.33M | $3.66M | $2.92M |
| Operating income | -$24.49M | -$20.51M | -$14.91M | -$10.22M | -$13.92M | -$13.72M | -$11.47M | -$12.24M |
| Interest expense | — | — | — | $0 | $0 | $0 | — | $1,000 |
| Pretax income | -$21.47M | -$17.82M | -$13.21M | -$8.33M | -$11.82M | -$12.32M | -$10.35M | -$11.40M |
| Income tax | -$19,000 | -$19,000 | -$20,000 | -$16,000 | -$15,000 | -$21,000 | -$11,000 | $16,000 |
| Net income | -$21.45M | -$17.80M | -$13.19M | -$8.32M | -$11.80M | -$12.30M | -$10.34M | -$11.41M |
| EBITDA | -$24.45M | -$20.48M | -$14.88M | -$10.19M | -$13.88M | -$13.68M | -$11.43M | -$12.21M |
| EPS (basic) | -0.13 | -0.11 | -0.09 | — | -0.08 | -0.09 | -0.09 | — |
| EPS (diluted) | -0.13 | -0.11 | -0.09 | — | -0.08 | -0.09 | -0.09 | — |
| Weighted avg. shares (diluted) | 159.73M | 156.60M | 145.59M | — | 145.10M | 130.35M | 117.61M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $27.85M | $54.30M | $19.41M | $18.91M | $56.87M | $117.06M | $19.37M | $34.10M |
| Short-term investments | $271.56M | $264.57M | $152.37M | $169.35M | $138.06M | $86.83M | $83.88M | $73.53M |
| Current assets | $305.80M | $325.70M | $176.12M | $191.66M | $198.30M | $207.23M | $105.62M | $109.43M |
| PP&E, net | $342,000 | $336,000 | $265,000 | $178,000 | $213,000 | $239,000 | $277,000 | $157,000 |
| Total assets | $310.81M | $330.52M | $179.61M | $193.44M | $199.36M | $208.34M | $107.00M | $110.90M |
| Current liabilities | $7.87M | $8.74M | $7.12M | $9.75M | $9.04M | $9.24M | $6.87M | $10.51M |
| Total liabilities | $8.06M | $9.01M | $7.48M | $10.20M | $9.57M | $9.85M | $7.55M | $11.26M |
| Shareholders' equity | $302.76M | $321.51M | $172.13M | $183.24M | $189.79M | $198.49M | $99.46M | $99.64M |
| Shares outstanding | 142.53M | 142.42M | 128.41M | 128.31M | 128.22M | 121.78M | 99.89M | 93.60M |
| Cash flow statement | ||||||||
| Operating cash flow | -$19.69M | -$17.43M | -$16.69M | -$7.63M | -$10.88M | -$10.10M | -$13.48M | -$9.55M |
| Capital expenditure | $25,000 | $124,000 | $102,000 | $0 | $12,000 | — | — | $7,000 |
| Free cash flow | -$19.71M | -$17.55M | -$16.79M | -$7.63M | -$10.89M | — | — | -$9.56M |
| Investing cash flow | -$7.18M | -$112.04M | $16.96M | -$30.61M | -$50.94M | -$2.61M | -$9.95M | -$23.87M |
| Financing cash flow | $412,000 | $164.36M | $222,000 | $284,000 | $1.63M | $110.39M | $8.71M | $51.47M |
| Depreciation & amortization | $41,000 | $34,000 | $34,000 | $31,000 | $38,000 | $38,000 | $37,000 | $38,000 |
| Stock-based compensation | $3.37M | $3.27M | $2.19M | $1.35M | $1.24M | $1.38M | $1.21M | $917,000 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.